Why Big Pharma Is Suddenly Taking Longevity Drugs Seriously

Business Insider reports that the 2026 Aging Research and Drug Discovery meeting marked a shift in how major drugmakers talk about longevity. Held in Boston after more than a decade in Europe, the conference brought together US regulators, large pharmaceutical companies, and biotech leaders to discuss drugs aimed at age-related decline. Executives from Pfizer, GSK, AstraZeneca, Novartis, and Eli Lilly were among those discussing “longevity drugs.”

The report highlights a key change: researchers are now discussing the frameworks and data the FDA would need to evaluate whether longevity drugs work. FDA clinical pharmacologist Justin Penzenstadler said the agency planned to release new clinical trial guidance next year and encouraged drugmakers to agree on trial design and data presentation. That matters because aging itself has not had a straightforward approval pathway.

New biological age and organ “clock” blood tests are giving researchers ways to estimate whether organs or the body appear to age faster or slower than expected. Eli Lilly and Novo Nordisk presented ARDD data on GLP-1 drugs, with Lilly pointing to tirzepatide’s possible effects on internal organs and Novo analyzing blood samples from more than 10,000 semaglutide trial participants. Business Insider notes that regulators will need much more than early data before approving a drug for aging.

The financial stakes are a major reason longevity is getting serious attention. TD Securities put the current longevity market at over $250 billion, excluding the $560 billion-plus market for traditional age-related disease care cited in the report. HSBC private bank projected that healthcare advances and more healthy years of labor force participation could contribute to a “12.5 trillion global GDP uplift” by 2050.

The central question is no longer whether drug companies should pursue longevity medicine, but whether they can prove their therapies work. A PROSPR longevity trial aims to test whether semaglutide can benefit healthy older adults without diabetes or obesity. For readers, the practical takeaway is to watch trial design, FDA guidance, and measurable functional outcomes—not just anti-aging claims.